Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Other Osteoporosis
Interventions
DRUG

Placebo tablet

one placebo once a week for two years followed by one 35 mg risedronate once a week for two years

DRUG

Risedronate

one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years

Trial Locations (23)

19610

Research Site, Wyomissing

34996

Research Site, Stuart

45219

Research Facility, Cincinnati

63110

Research Site, St Louis

80227

Research Site, Lakewood

92260

Research Site, Palm Desert

97239

Research Site, Portland

Unknown

Research Facility, Concord

Research Facility, Heidelburg

Research Facility, Leuven

Research Site, Prague

Research Facility, Angers

Research Site, Lyon

Research Facility, Budapest

Research Site, Budapest

Research Site, Beirut

Research Site, Rotterdam

Research Site, Bialystok

Research Site, Warsaw

Research Site, Wroclaw

Research Site, London

Research Site, Newcastle

Research Site, Sheffield

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Warner Chilcott

INDUSTRY